Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Kelly Executive Medical Director, MD
Syros Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu Lyon Sud
Pierre-Bénite, Pierre Benite, France
- Chu Angers
Angers, France
- Ch de la Côte Basque
Bayonne, France
- Hôpital Avicenne Hématologie Clinique
Bobigny, France
- Chu de Caen Normandie
Caen, France
- Chu Limoges
Limoges, France
- Chu de Nantes - Hôtel Dieu
Nantes, France
- Hôpital L'Archet- Chu de Nice
Nice, France
- Chu de Bordeaux - Hôpital Haut-Lévèque
Pessac, France
- Chu de Poitiers
Poitiers, France
- Hôpital Saint-Louis
Vellefaux, France
- Centre Hospitalier de Versailles
Versailles, France
- Institut Gustave Roussy
Villejuif, France
- City of Hope
Duarte, California, United States
- Ucla Medical Center Division of Hematology/oncology
Los Angeles, California, United States
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute
Denver, Colorado, United States
- University of Colorado
Denver, Colorado, United States
- Hartford Healthcare
Hartford, Connecticut, United States
- Northside
Atlanta, Georgia, United States
- University of Mississippi
Jackson, Mississippi, United States
- Hca Midwest Research Medical Center
Kansas City, Missouri, United States
- Atlantic Health
Morristown, New Jersey, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Novant Health
Charlotte, North Carolina, United States
- the Ohio State University James Cancer Hospital
Columbus, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Aug 2021
- Primary completion
- 12 Aug 2024
- Completion
- 12 Aug 2024
- Last update posted
- 24 Feb 2025
- Registered enrollment
- 66
- Registry id
- NCT04905407
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.